Core Viewpoint - The company emphasizes its commitment to fair information disclosure by providing shareholder numbers in regular reports and allowing investors to verify their holdings through written documentation [1] Group 1 - The company will disclose the number of shareholders at the time of regular report releases [1] - For other months, investors can request shareholder numbers by providing proof of their shareholdings [1] - The company will verify shareholder identities before providing the requested information [1]

Core Insights - Jinghua Pharmaceutical's stock increased by 0.25% on November 11, with a trading volume of 182 million yuan, indicating active market participation [1] - The company reported a financing buy of 12.04 million yuan and a financing repayment of 16.41 million yuan on the same day, resulting in a net financing outflow of 4.37 million yuan [1] - As of November 11, the total margin balance for Jinghua Pharmaceutical was 177 million yuan, representing 2.71% of its market capitalization [1] Financing and Margin Data - On November 11, the financing buy amounted to 12.04 million yuan, while the current financing balance stands at 177 million yuan, which is above the 70th percentile of the past year [1] - The short selling data shows no shares were sold or repaid on November 11, with a remaining short position of 2,000 shares and a short balance of 16,000 yuan, indicating a low level of short selling activity [1] Company Overview - Jinghua Pharmaceutical, established on January 3, 1994, and listed on February 3, 2010, is based in Nantong, Jiangsu Province [1] - The company's main business includes the research, production, and sales of traditional Chinese medicine preparations, chemical raw materials, and biopharmaceuticals [1] - The revenue composition is as follows: traditional Chinese medicine preparations (39.22%), chemical pharmaceutical intermediates (23.51%), chemical raw materials (20.79%), and Chinese medicinal materials (15.80%) [1] Financial Performance - For the period from January to September 2025, Jinghua Pharmaceutical achieved a revenue of 1.092 billion yuan, reflecting a year-on-year growth of 4.51% [2] - The net profit attributable to shareholders for the same period was 176 million yuan, showing a year-on-year increase of 7.39% [2] Shareholder and Dividend Information - Since its A-share listing, Jinghua Pharmaceutical has distributed a total of 533 million yuan in dividends, with 205 million yuan distributed over the past three years [3] - As of September 30, 2025, the number of shareholders decreased by 7.36% to 88,800, while the average number of circulating shares per person increased by 7.94% to 9,167 shares [2][3] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 6.8555 million shares, a decrease of 1.6727 million shares from the previous period [3]

分组1 - Midea Group announced a cash dividend distribution plan for the 2025 mid-term A-shares, distributing 5 yuan per 10 shares, totaling 3.448 billion yuan [1] - Huayuan Communication is planning a change in control and will suspend trading of its stock starting November 12, 2025, for up to two trading days [2] - Shangwei New Materials reported a significant stock price increase of 1573.52% from July 9 to November 11, 2025, but its new intelligent robot business is still in the development stage and has not generated revenue [3] 分组2 - Shannon Chip announced that shareholder Shenzhen Xinlianpu pledged 1.27 million shares, accounting for 5.55% of its holdings and 0.27% of the total share capital [4] - Tianji Co., Ltd. reported that its controlling shareholder pledged 39.965 million shares for its own production and operation, representing 64.79% of its holdings and 7.97% of the total share capital [5] - ST Zhengping completed its stock trading situation review and will resume trading on November 12, 2025, with no significant changes in its production and operation [6] 分组3 - Furi Co. reported that its subsidiary Furi New Energy is facing risks of losses despite a 47.78% year-on-year increase in revenue to 168.3981 million yuan for the first three quarters of 2025 [7] - Wentai Technology announced that major shareholders reduced their holdings by 12.4443 million shares, completing the reduction plan [8] 分组4 - Anke Biotech signed a framework agreement for exclusive agency of PA3-17 injection, a CAR-T cell therapy product, in Greater China [9] - Tongxing Technology plans to invest approximately 3.2 billion yuan in a project to produce 100,000 tons of sodium-ion battery cathode materials and 6 GWh of battery cells [10] - Redik plans to establish a joint venture for the development of robotic components, with a registered capital of 100 million yuan [11] 分组5 - Haike New Source signed a strategic cooperation agreement with Kunlun New Materials for the purchase of 596,200 tons of electrolyte solvent over three years [12] - World announced that its diamond micro-drill products for PCB processing are still in the R&D phase and have not generated revenue [13] 分组6 - Xiamen Airport reported a 1.56% year-on-year increase in passenger throughput for October [14] - New City Holdings reported a 7.65% year-on-year increase in total commercial operating revenue for October [15] - Huadong Holdings announced a 0.65% year-on-year decrease in pig sales revenue for October [15] 分组7 - Keykai Technology's controlling shareholder plans to transfer 3% of its shares [15] - Zhongyou Engineering won a joint bid for a project worth approximately 3 billion yuan in Kazakhstan [15] - Weiteng Electric plans to raise no more than 300 million yuan through a private placement for smart manufacturing projects [15]

分组1 - Midea Group announced a cash dividend distribution plan for the 2025 interim A-shares, proposing a payout of 5 yuan for every 10 shares, totaling 3.448 billion yuan [2] - Huayuan Communication is planning a change in control and will suspend trading of its stock starting November 12, 2025, for up to two trading days [3] - Shangwei New Materials reported a significant stock price increase of 1573.52% from July 9 to November 11, 2025, but its new intelligent robot business is still in the product development stage and has not yet generated revenue [4] 分组2 - Shannon Chip announced that shareholder Shenzhen Xinlianpu has pledged 1.27 million shares, accounting for 5.55% of its holdings and 0.27% of the total share capital, for financing purposes [5] - Tianji Co., Ltd. disclosed that its controlling shareholder has pledged 39.965 million shares for its own production and operation, representing 64.79% of its holdings and 7.97% of the total share capital [6] - ST Zhengping completed its stock trading situation review and will resume trading on November 12, 2025, with no significant changes in its production and operation [7] 分组3 - Furi Co., Ltd. reported that its subsidiary Furi New Energy is facing a risk of losses despite a 47.78% year-on-year increase in revenue to 168.3981 million yuan for the first three quarters of 2025 [8] - Wentai Technology announced that major shareholders have reduced their holdings by 12.4443 million shares, completing the reduction plan [9] - Anke Biotech signed a framework agreement for exclusive agency of the PA3-17 injection product in Greater China, which is a CAR-T cell therapy for certain cancers [10] 分组4 - Tongxing Technology plans to invest approximately 3.2 billion yuan in a project to produce 100,000 tons of sodium-ion battery cathode materials and 6GWh battery cells [11] - Redick is collaborating with Aoyi Technology to establish a joint venture for the development of robotic components, with a registered capital of 100 million yuan [12] - Haike New Source signed a strategic cooperation agreement with Kunlun New Materials for the purchase of 596,200 tons of electrolyte solvent over a two-year period [13] 分组5 - World announced that its diamond micro-drills for PCB processing are still in the research and testing phase, with limited revenue impact [14][15] - Huadong Holdings reported a 0.65% year-on-year decline in pig sales revenue for October [16] - Keykai Technology's controlling shareholder plans to transfer 3% of its shares through an inquiry [17]

Core Viewpoint - Jinghua Pharmaceutical has received approval from the National Medical Products Administration for two drug registration certificates for its controlled-release capsules of carbidopa and levodopa, enhancing its product pipeline in the Parkinson's disease treatment sector [1] Group 1: Product Approval - The company is the third entity in China to obtain approval for the controlled-release capsules of carbidopa and levodopa (specification: carbidopa 50mg, levodopa 200mg) [1] - The controlled-release capsules (specification: carbidopa 25mg, levodopa 100mg) represent the first generic version in China, with the original product not registered for sale domestically [1] Group 2: Market Opportunities - The approval of the controlled-release capsules enriches the company's product offerings in the Parkinson's disease treatment field [1] - The introduction of the small specification product as the first generic in the domestic market provides the company with additional business opportunities in this niche market [1]

Core Viewpoint - The approval of the controlled-release formulation of Carbidopa-Levodopa by the National Medical Products Administration enhances the company's product pipeline in the Parkinson's disease treatment sector, particularly with the introduction of a first generic version in the domestic market [1] Group 1: Product Approval - The company received two drug registration certificates for Carbidopa-Levodopa controlled-release tablets [1] - The specifications for the approved products include Carbidopa 50mg and Levodopa 200mg, and Carbidopa 25mg and Levodopa 100mg [1] - The latter specification is the first generic version in China, as the original product has not been registered for sale domestically [1] Group 2: Market Impact - The approval enriches the company's offerings in the Parkinson's disease treatment market, providing a significant opportunity in a niche segment [1] - The controlled-release formulation is recognized as the "gold standard" for treating Parkinson's disease according to the "Chinese Parkinson's Disease Treatment Guidelines (2020 Edition)" [1] - The availability of the smaller dosage form improves medication convenience for patients with mild symptoms [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for two drug registration certificates for Carbidopa-Levodopa Extended-Release Tablets, enhancing its product pipeline in the Parkinson's disease treatment sector [1] Group 1: Product Approval - The Carbidopa-Levodopa Extended-Release Tablets (specification: Carbidopa 50mg, Levodopa 200mg) is the third approved product in the domestic market [1] - The Carbidopa-Levodopa Extended-Release Tablets (specification: Carbidopa 25mg, Levodopa 100mg) is the first generic version in the domestic market, with no original product registered for sale [1] Group 2: Market Opportunities - The approval of these products expands the company's opportunities in the Parkinson's disease treatment market [1] - The new products may lead to increased business prospects in this niche market [1] Group 3: Sales Uncertainty - The production and sales of the drugs may be influenced by changes in the market environment and other comprehensive factors, leading to certain uncertainties in sales performance [1]

Core Viewpoint - The approval of the sustained-release formulation of Carbidopa-Levodopa by the National Medical Products Administration enhances the company's product pipeline in the Parkinson's disease treatment sector, particularly with the introduction of a first generic version in the domestic market [1] Group 1: Product Approval - The company has received two drug registration certificates for Carbidopa-Levodopa sustained-release tablets [1] - The product specifications include Carbidopa 50mg and Levodopa 200mg, making the company the third entity in China to obtain approval for this formulation [1] - The smaller specification of Carbidopa 25mg and Levodopa 100mg is the first generic version in China, with no original research product registered for sale domestically [1] Group 2: Market Impact - The approval enriches the company's offerings in the Parkinson's disease treatment market, providing a significant opportunity in a niche segment [1] - The sustained-release formulation is recognized as the "gold standard" for treating Parkinson's disease according to the "Chinese Parkinson's Disease Treatment Guidelines (2020 Edition)" [1] - The successful approval of the product offers a viable original research alternative for Parkinson's disease patients, particularly benefiting those with mild symptoms through the availability of smaller dosage options [1]

证券代码：002349 证券简称：精华制药 公告编号：2025-047 精华制药集团股份有限公司 关于公司产品获得药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或者重大遗漏。 近日，精华制药集团股份有限公司（以下简称"公司"）收到国家药品监督 管理局核准签发的卡左双多巴缓释片的两个《药品注册证书》，现就相关情况公 告如下： 一、药品注册批准情况 （1）证书编号：2025S03317 药品名称：卡左双多巴缓释片 主要成分：卡比多巴、左旋多巴 剂 型：片剂 申请事项：药品注册（境内生产） 包装规格：10 片/板，3 板/盒 处方药/非处方药：处方药 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、 标签及生产工艺照所附执行。药品生产企业应当符合药品生产质量管理规范要求 方可生产销售。 上市许可持有人：精华制药集团股份有限公司 生产企业：精华制药集团股份有限公司 证券代码：002349 证券简称：精华制药 公告编号：2025-047 规 格：卡比多巴 25mg（按 C₁ ...

Group 1 - The company has decided to abolish the supervisory board and amend its articles of association accordingly, which was approved in the meetings held on August 28, 2025, and September 17, 2025 [2] - The company has completed the registration capital change and the cancellation of the supervisory board, obtaining a new business license from the Nantong Data Bureau [3] - The company's registered capital is approximately 829.67 million yuan, and it operates in various sectors including the production and sale of pharmaceuticals and health products [4] Group 2 - The company is located in Nantong City, Jiangsu Province, and was established on January 3, 1994 [4] - The legal representative of the company is Yin Hongyu [4] - The company’s business scope includes the production, processing, and sales of various pharmaceutical forms, as well as import and export activities related to its production needs [3]